The Procter Gamble Company

Gary Lee Manring

Gary Robert Kelm

Douglas Joseph Dobrozsi

Kenneth Gary Mandel

Paula Denise Davis

Mahdi B Fawzi

Brian D Barford

Andrew W Fulmer

Edward D Thompson

Stephen B Carter

David Lee McCauley-Meyers

The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:

Pharmaceutical dosage form for colonic delivery

The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising: a. a safe and effective amount of a therapeutically active agent incorporated into or coated on the surface of a dosage form selected from the group consisting of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed tablet, with a maximum diameter of about 3 mm to about 10 mm; and b. an enteric polymer coating material comprising at least one inner coating layer and one outer coating layer; wherein the dosage form has a smooth surface free from edges or sharp curves; the elliptical substrate and the hard capsule have a ratio of the long to short diameters of no greater than about 1.5; the therapeutically active agent is released at a point near the inlet to, or within the colon; each of the inner coating layer(s) is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 5 to about 6.3; and the outer coating layer is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 6.8 to about 7.2.

Pharmaceutical dosage form with multiple enteric polymer coatings for

Bisacodyl dosage form with multiple enteric polymer coatings for colonic

Bisacodyl dosage form for colonic delivery

The present invention relates to shampoo compositions comprising at least about 0.1% of a water insoluble anti-inflammatory agent, from about 5% to about 40% of a synthetic surfactant and water.

Shampoo compositions comprising water-insoluble particulate

Topical pharmaceutical compositions, containing clindamycin phosphate, a zinc fatty acid salt, such as zinc acetate, and a non-aqueous vehicle, are disclosed. The compositions provide antibiotic performance and are present as physically stable, aesthetically-pleasing, clear, ringing gels, without requiring the use of conventional gelling agents. The method of topically treating clindamycin responsive dermatoses, such as acne, using these compositions is also disclosed.

Gel-form topical antibiotic compositions

Compositions for topical application of erythromycin and derivatives or erythromycin comprising ethanol, isopropyl myristate, glycerol monooleate and the erythromycin compounds are especially useful as a treatment for acne.

Growing community of inventors

Hamilton, OH, United States of America

Gary Lee Manring